Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.

This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.

This paper discusses the first reported case of post-finasteride syndrome in a long-term dermatotrichology setting, occurring in a 25-year-old male after dutasteride treatment, and highlights possible links to mental health disorders.

This study found that reports of suicidal ideations linked to oral finasteride were significantly higher in 2013–2018 and 2019–2023 compared to 2006–2011, potentially due to increased awareness of post-finasteride syndrome from 2012 onward. No such signals were seen with oral dutasteride.

This article reviews factors influencing hair growth, with emphasis on androgenetic alopecia, and reports no clinical findings; the authors emphasize the role of androgens and mention treatments like finasteride, dutasteride, and minoxidil.

In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.

This review identified emerging therapies for androgenetic alopecia, such as low-dose oral minoxidil and stem cell-based treatments, which show promise for improved hair loss management but require standardized protocols and large-scale trials for further validation.

This study proposes that the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia may contribute to poorer COVID-19 prognosis in males.

This study identified distinct and significant adverse event patterns across different drug classes used to treat benign prostatic hyperplasia, confirming known risks and suggesting novel safety signals for further investigation.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

This study discusses the potential of topical retinoids, vitamin A derivatives, to improve treatment outcomes for androgenetic alopecia by promoting hair growth through extending the anagen phase and stimulating follicular activity, offering a promising approach when combined with existing therapies.

This article highlights that in Australia, transgender and gender-diverse patients experience specific dermatological challenges during gender-affirming treatments, such as acne and patterned hair loss. It emphasizes the need for tailored dermatological care and guidance for these patients.

This review explores plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, for their potential use as alternative treatments for prostate cancer, emphasizing their effects on 5-alpha-Reductase enzyme isozymes. It reports no new clinical results.

This study found that in male mouse pancreatic islet β cells, testosterone enhances glucose-stimulated insulin secretion by being locally converted into dihydrotestosterone and estradiol.

This review found that adding α1-blockers to 5α-reductase inhibitors may improve lower urinary tract symptoms in men with non-neurogenic conditions, based on existing evidence.

In this study, ginsenoside 20(S)-protopanaxadiol-aglycone (PPD) was shown to downregulate androgen receptor expression and inhibit tumor growth in prostate cancer cells.

This study observed that uncommon finasteride side effects included melasma, dry skin, tinnitus, postural hypotension, and oral lesions, with some symptoms persisting after treatment cessation.

This study found that adverse effects of finasteride were more common among right-handed heterosexuals and left-handed homosexuals with androgenic alopecia.

This report describes a rare case of cyclophosphamide-associated neutrophilic folliculitis, suggesting its inclusion in differential diagnoses for acneiform eruptions.

This study highlights nasopharyngeal carcinoma as the fourth most common cancer in Indonesia, noting that its etiology involves genetic and environmental factors, while early detection often utilizes serology and imaging, with diagnosis confirmed by biopsy and histopathology.

This study found that both Clomiphene Citrate and Human Chorionic Gonadotropin were effective in restoring testosterone levels in men with hypogonadism, as demonstrated in a short-course randomized study.

This review discusses current and emerging treatments for androgenic alopecia, noting that minoxidil and finasteride are the only FDA-approved options, while other methods lack comparable evidence of efficacy.

This review discusses the potential benefits and risks of 5α-reductase inhibitors in preventing prostate cancer and reports no new results.

Both drugs lower DHT levels, with GI198745 being more effective.

This systematic review suggests that current evidence does not support routinely discontinuing gender-affirming hormone treatments before surgery, especially testosterone and spironolactone, due to limited data on related perioperative risks.

This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This case report found that a woman's hair loss, which progressed while using spironolactone and topical minoxidil, reversed after switching to flutamide therapy.

In this study, there was no evidence that using 5α-reductase inhibitors for either short or long durations increased the risk of male breast cancer.

This article discusses the surgical technique of "deroofing" for hidradenitis suppurativa, highlighting its advantages over traditional methods but reports no new clinical results; the authors emphasize the importance of dietary management as part of treatment.